Evidence mapPaperPMID 40392243Full record

ReviewMolecular biology reports2025

Mitochondrial dysfunction in epilepsy: mechanistic insights and clinical strategies.

Xiaolu Zhang, Zhengjuan Wu, Xu Zhou, Hua Tao

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Exploring the causal impact of mitochondrial dysfunction on epilepsy: a mendelian randomization study.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiaolu Zhang *Department of Neurology, Affiliated Hospital of Guangdong Medical University, NO.57, Renmindadaonan Road, Xiashan District, Zhanjiang, 524001, Guangdong, China.
Zhengjuan Wu *Department of Neurology, Affiliated Hospital of Guangdong Medical University, NO.57, Renmindadaonan Road, Xiashan District, Zhanjiang, 524001, Guangdong, China.
Xu ZhouClinical Research and Experimental Center, Affiliated Hospital of Guangdong Medical University, NO.57, Renmindadaonan Road, Xiashan District, Zhanjiang, 524001, Guangdong, China.
Hua TaoDepartment of Neurology, Affiliated Hospital of Guangdong Medical University, NO.57, Renmindadaonan Road, Xiashan District, Zhanjiang, 524001, Guangdong, China. taohua1943@126.com.

Funding

Funds for High-Level Talents in the Affiliated Hospital of Guangdong Medical University GCC2023011Natural Science Foundation of Guangdong Province 2022A1515012615the Guangdong Provincial Fund for Basic and Applied Basic Research Joint Fund with Enterprises 2024A1515220082
6 · The paper itself

Abstract

Epilepsy is a common neurological disorder that is increasingly recognized for its significant association with mitochondrial dysfunction. This review explores the intricate relationship between mitochondrial dysfunction and epilepsy, highlighting the molecular mechanisms, diagnostic strategies, and therapeutic approaches involved. Mitochondrial abnormalities, including defects in the electron transport chain, impaired mitochondrial dynamics, disrupted autophagy, and increased oxidative stress, are implicated in epilepsy pathogenesis. The molecular mechanisms involve respiratory chain impairments, fission-fusion imbalances, inadequate mitophagy, and oxidative stress-induced neuronal excitability. The diagnosis of mitochondrial epilepsy requires a multifaceted approach, combining clinical assessment, biochemical testing, imaging, and genetic analysis, with a particular focus on mtDNA mutations. Therapeutic strategies include antiepileptic drugs with variable mitochondrial effects, the ketogenic diet, and emerging potential approaches such as antioxidants and mitochondrial-targeted therapies. Despite advances in understanding and treatment, challenges persist due to the complexity of mtDNA mutations and treatment resistance. Future directions involve gene-editing technologies, mitochondrial transplantation, and induced pluripotent stem cells, which hold promise for addressing the underlying defects and improving epilepsy management.

Indexed as

EpilepsyMitochondriaMitochondrial DiseasesAnimalsAnticonvulsantsDiet, KetogenicDNA, MitochondrialElectron TransportHumansMitochondrial DynamicsMutationOxidative StressAnticonvulsantsDNA, MitochondrialEpilepsyKetogenic dietMitochondriaMutationOxidative stress

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.